NitroMed
Emerging pharmaceutical company with substantial expertise and intellectual property in nitric oxide-based drug development.
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Series A | |
N/A | N/A | Series B | |
N/A | N/A | Series C | |
N/A | N/A | Series D | |
$31.4m | Series E | ||
N/A | N/A | IPO | |
N/A | Acquisition | ||
Total Funding | AUD48.5m |